Chemomab Therapeutics Ltd. CMMB

CMMB Quotes by TradingView
Institutional shares held 4 Million
0 calls
0 puts
Total value of holdings $5.44M
$0 calls
$0 puts
Market Cap $15.5M
11,431,700 Shares Out.
Institutional ownership 34.98%
# of Institutions 17

Quarterly Institutional Activity in CMMB

Shares Bought
Shares Sold
View Transactions

Top Institutions Holding CMMB

View all
View all

Latest Institutional Activity in CMMB

Top Purchases

Q1 2025
Wetzel Investment Advisors, Inc. Shares Held: 11K ($15K)
1K Shares purchased
10.0% Added
Q1 2025
Rhumbline Advisers Shares Held: 23.8K ($32.4K)
41 Shares purchased
0.17% Added
Q1 2025
Sbi Securities Co., Ltd. Shares Held: 104 ($141)
4 Shares purchased
4.0% Added
Q4 2024
Virtu Financial LLC Shares Held: 14.4K ($19.6K)
14.4K Shares purchased
New Holding
Q4 2024
Xtx Topco LTD Shares Held: 24.9K ($33.9K)
9.71K Shares purchased
63.76% Added
View All Buyers

Top Sells

Q1 2025
Yelin Lapidot Holdings Management Ltd. Shares Held: 578K ($786K)
166K Shares sold
22.29% Reduced
Q1 2025
Gamma Investing LLC Shares Held: 11K ($15K)
993 Shares sold
8.26% Reduced
Q4 2024
Morgan Stanley Shares Held: 104K ($142K)
298K Shares sold
74.05% Reduced
Q4 2024
Ubs Group Ag Shares Held: 485 ($660)
1.8K Shares sold
78.8% Reduced
Q4 2024
Boothbay Fund Management, LLC Shares Held: 26.2K ($35.6K)
340 Shares sold
1.28% Reduced
View All Sellers

About CMMB

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

CMMB Chart by TradingView
CMMB Fundamental Data by TradingView

Insider Transactions at CMMB

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
Jan 03 2023
Orbi Med Israel Gp Ltd. > 10% Shareholder
SELL
Open market or private sale
Indirect
336,900 -6.69%
$1,010,700 $3.93 P/Share
Jan 03 2023
George Adi Mor Chief Scientific Officer
SELL
Open market or private sale
Indirect
6,100 -2.37%
$30,500 $5.03 P/Share
Jan 03 2023
George Adi Mor Chief Scientific Officer
SELL
Open market or private sale
Direct
7,700 -2.37%
$38,500 $5.03 P/Share
Nov 16 2022
Neil Harris Cohen Director
SELL
Open market or private sale
Direct
2,409 -19.41%
$4,818 $2.0 P/Share
Nov 16 2022
George Adi Mor Chief Scientific Officer
SELL
Open market or private sale
Indirect
257,248 -50.0%
$514,496 $2.08 P/Share
Nov 16 2022
George Adi Mor Chief Scientific Officer
SELL
Open market or private sale
Direct
324,775 -50.0%
$649,550 $2.08 P/Share
May 24 2022
Joel Michael Maryles Director
BUY
Open market or private purchase
Direct
433 +12.24%
$866 $2.83 P/Share
May 18 2022
Neil Harris Cohen Director
BUY
Open market or private purchase
Direct
2,000 +13.88%
$6,000 $3.19 P/Share
Mar 18 2022
Joel Michael Maryles Director
BUY
Open market or private purchase
Direct
1,000 +41.67%
$4,000 $4.34 P/Share
Mar 16 2022
Donald Marvin Executive VP, CFO & COO
BUY
Open market or private purchase
Direct
500 +11.81%
$1,500 $3.28 P/Share
Mar 14 2022
Neil Harris Cohen Director
BUY
Open market or private purchase
Direct
6,000 +19.71%
$24,000 $4.35 P/Share
Mar 14 2022
Dale R Pfost Chief Executive Officer
BUY
Open market or private purchase
Direct
2,500 +35.94%
$7,500 $3.98 P/Share
Mar 11 2022
Nissim Darvish Director
BUY
Open market or private purchase
Direct
1,200 +50.0%
$4,800 $4.28 P/Share
Dec 06 2021
Neil Harris Cohen Director
BUY
Open market or private purchase
Direct
2,000 +31.21%
$14,000 $7.43 P/Share
Mar 16 2021
Neil Harris Cohen Director
BUY
Open market or private purchase
Direct
2,409 +50.0%
$98,769 $41.51 P/Share
Mar 16 2021
Peter Thiel > 10% Shareholder
BUY
Open market or private purchase
Indirect
230,536 +17.22%
-
Mar 16 2021
Orbi Med Israel Gp Ltd. > 10% Shareholder
BUY
Grant, award, or other acquisition
Indirect
288,170 +10.05%
$4,898,890 $17.35 P/Share
View All Transactions

Last 12 Months Summary

Buy / Acquisition
0 Shares
From 0 Insiders
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on CMMB

Follow Chemomab Therapeutics Ltd. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CMMB shares.

Notify only if
Any

Insider Trading

Get notified when an Chemomab Therapeutics Ltd. insider buys or sells CMMB shares.

Notify only if
Any
Any
P - Open market or private purchase×
S - Open market or private sale×
V - Transaction voluntarily reported earlier than required×
A - Grant, award, or other acquisition×
D - Sale (or disposition) back to the issuer×
F - Payment of exercise price or tax liability×
I - Discretionary transaction×
M - Exercise of conversion of derivative security×
C - Conversion of derivative security×
E - Expiration of short derivative position×
H - Expiration (or cancellation) of long derivative position with value received×
O - Exercise of out-of-the-money derivative securities×
X - Exercise of in-the-money or at-the-money derivatives securities×
G - Bona fide gift×
L - Small Acquisition×
W - Acquisition or disposition by will or laws×
Z - Deposit into or withdrawal from voting trust×
J - Other acquisition or disposition×
K - Transaction in equity swap or similar instrument×
U - Disposition due to a tender of shares in a change of control transaction×
20 item(s) selected

News

Receive news related to Chemomab Therapeutics Ltd.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on CMMB